Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

ClinicalTrials.gov ID: NCT06469944

Public ClinicalTrials.gov record NCT06469944. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C

Study identification

NCT ID: NCT06469944
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Enrollment: 160 participants

Conditions and interventions

Conditions

Interventions

5-Fluorouracil (5-FU) Drug
Capecitabine Drug
Leucovorin Drug
Levoleucovorin Drug
Oxaliplatin Drug
Patritumab Deruxtecan Biological
Pembrolizumab Biological
Sacituzumab Tirumotecan (sac-TMT) Biological

Drug · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 19, 2024
Primary completion: Sep 11, 2029
Completion: Sep 11, 2029
Last update posted: Apr 30, 2026

2024 – 2029

United States locations

U.S. sites: 8
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927)	Tucson	Arizona	85719	Recruiting
UCLA Hematology/Oncology - Santa Monica ( Site 6905)	Los Angeles	California	90404	Recruiting
Norton Hospital-Norton Cancer Institute - Downtown ( Site 6900)	Louisville	Kentucky	40202	Completed
The Cancer and Hematology Centers ( Site 6912)	Grand Rapids	Michigan	49503	Recruiting
Hematology-Oncology Associates of Central NY, P.C. ( Site 6925)	East Syracuse	New York	13057	Recruiting
Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 6907)	New York	New York	10032	Completed
UPMC Hillman Cancer Center-UPMC ( Site 6904)	Pittsburgh	Pennsylvania	15232	Recruiting
University of Texas MD Anderson Cancer Center ( Site 6920)	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06469944, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 30, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06469944 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →